01:33 AM EST, 11/12/2026 (MT Newswires) -- Bernstein trimmed its price target for Alcon (ALC.SW) to 72.75 francs from 76.15 francs after a "challenging" third quarter, while expecting upcoming product launches to support the Swiss eye care company's future growth. "We remain Outperform Alcon, which we see as a dominant player in long-term attractive end-markets. Q3 was a low point for the high margin Implantables business and competitive pressures will persist in Q4 and into Q1 2027E. However, we still see this as transitory with Alcon set to benefit from upcoming product launches and its broader innovation pipeline, starting with the Vivity Pro launch in January. As a leader in ophthalmology, the company is also expanding into white spaces with Neurotech, Valeda and Aurion, providing additional opportunities for growth," analysts said Thursday. Alcon reported a 5% year-over-year rise in third-quarter net sales to $2.72 billion, also up 5% at constant currency, and saw core diluted EPS grow 15% on an actual and constant-currency basis to $0.91. The research firm noted constant-currency revenue growth missed consensus forecasts of 6%, while the core EPS beat market expectations by 3%. The company also tightened its full-year 2026 outlook, including constant-currency net sales growth outlook of 6% versus the previous goal of 5% to 7% and core diluted EPS growth of 12% to 14% at constant currency, compared with the 12% to 15% range previously. Against this backdrop, Bernstein trimmed its adjusted EPS assumptions for 2026 and 2027 to 3.51 euros and 3.94 euros, respectively, from 3.53 euros and 4.20 euros.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.